Skip to main content

Table 1 Charecteristics of SS, AS, S/βThal patients and controls. Data are presented as mean ± SD for the age and hematological data and frequency for sex and clinical complications

From: Factor V Leiden G1691A and prothrombin G20210A mutations among Palestinian patients with sickle cell disease

 

AS (n = 25)

SS (n = 59)

S/βThal (n = 33)

Controls (n = 118)

Sex, F/M

11/14

29/30

15/18

41/77

Age, years

21.2 ± 9.1

16 ± 9.9

15.1 ± 5.1

20.6 ± 5.5

Hematological data

 Hb (mg/dL)

12.9 ± 1.67

8.4 ± 1.09

8.32 ± 1.33

14.1 ± 1.58

 MCV (fL)

81.4 ± 7.39

87.4 ± 8.0

69.16 ± 7.91

85.2 ± 4.08

 MCH (pg)

26.78 ± 2.91

28.7 ± 2.88

23.34 ± 3.41

31.1 ± 2.76

 HbF (%)

1.1 ± 0.63

5.14 ± 3.3

7.98 ± 3.43

0.9 ± 0.23

 HbS (%)

36.3 ± 6.1

86.6 ± 7.4

69.8 ± 10.56

0

 Hb A2 (%)

2.61 ± 0.41

2.1 ± 0.52

4.46 ± 0.74

2.4 ± 0.52

Clinical complications

 DVT

0

0

3

0

 Stroke

0

3

1

0

 Priapism

0

2

0

0

 Leg ulcers

0

9

0

0

 AVN

0

5

2

0

  1. Hb hemoglobin, MCV mean corpuscular volume, MCH mean corpuscular hemoglobin, HbF hemoglobin F, HbS hemoglobin S, HbA2 hemoglobin A2. AS Sickle cell trait, SS Sickle cell anemia, S/βThal Sickle β-thalassemia, DVT deep vein thrombosis, AVN avascular bone necrosis